FDA reportedly eyeing staff bonuses to accelerate drug reviews
Source: SeekingAlpha
2026-02-26 13:35:52 ET
More on leading drugmakers
- Health Care Q4 Dividend Roundup: Merck Offers Thicker Dividend Cushion Than AbbVie
- Johnson & Johnson: Strong Run May Be Ending (Rating Downgrade)
- Merck: Why Investors Should Remain Bullish Despite Patent Risks
- Kenvue effort to dismiss Tylenol case rejected by Texas judge
- CDC advisory meeting in March to focus on COVID-19 vaccine injuries, long COVID
Read the full article on Seeking Alpha
For further details see:
FDA reportedly eyeing staff bonuses to accelerate drug reviews
Sanofi
NASDAQ: SNYNF
SNYNF Trading
-4.91% G/L:
$88.50 Last:
727 Volume:
$90.68 Open:
SNYNF Latest News
March 05, 2026 03:16:37 am
Press Release: Sanofi's Board of Directors proposes the appointment of Christel Heydemann as an independent director
March 04, 2026 12:30:40 pm
Press Release: Filing of an amendment to the French "Document d'Enregistrement Universel" containing the Annual Financial Report
March 02, 2026 01:00:00 am
Press Release: Sanofi's rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease
SNYNF Stock Data
$121,583,170,304
1,228,540,835
N/A
1460
N/A
Pharmaceuticals
Healthcare
FR
Paris
